{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:06:35Z","timestamp":1793261195244,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373284"],"award-info":[{"award-number":["82373284"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373903"],"award-info":[{"award-number":["82373903"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glioblastoma multiforme (GBM) is a lethal primary brain cancer with limited treatment options. Systemic and local immunosuppression induced by GBMs contributes to malignancy aggressiveness and resistance to immune checkpoint blockade (ICB) therapy. Herein, we demonstrated that a novel oncolytic virus, M1 (OVM), reversed GBM-driven systemic immunosuppression and promoted T lymphocyte infiltration within the tumor microenvironment (TME). Intravenous administration of OVM suppressed glioma progression in a spleen-dependent manner. Mechanistically, OVM enhanced B-cell\u2013T-cell interactions in the spleen through the formation of immune synapses. A subset of B cells positive for bone marrow stromal cell antigen 2 (Bst2) was enriched in the splenic marginal zone following OVM treatment and exhibited superior capacity for antigen cross-presentation. These splenic Bst2\n                    <jats:sup>+<\/jats:sup>\n                    B cells activated cognate CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells to mediate adaptive antitumor immunity against intracranial gliomas. Moreover, OVM treatment synergized with anti-PD-1 therapy and further extended the survival of glioma-bearing animals. Collectively, our findings highlight the therapeutic potential of intravenous OVM for GBM management and reveal a novel immunomodulatory mechanism underlying oncolytic virotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s41423-026-01396-w","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:18:05Z","timestamp":1772619485000},"page":"349-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oncolytic virus M1 reinvigorates CD8+ T-cell immunity against glioblastoma through B-cell-dependent antigen cross-presentation in the spleen"],"prefix":"10.1038","volume":"23","author":[{"given":"Yu","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggao","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"1396_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306\u201316.","journal-title":"JAMA"},{"key":"1396_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1003\u201310.","journal-title":"JAMA Oncol"},{"key":"1396_CR3","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1093\/brain\/awaa343","volume":"143","author":"K Ayasoufi","year":"2020","unstructured":"Ayasoufi K, Pfaller CK, Evgin L, Khadka RH, Tritz ZP, Goddery EN, et al. Brain cancer induces systemic immunosuppression through release of nonsteroid soluble mediators. Brain. 2020;143:3629\u201352.","journal-title":"Brain"},{"key":"1396_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17:31.","journal-title":"J Hematol Oncol"},{"key":"1396_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36:1419\u201327.","journal-title":"J Clin Oncol"},{"key":"1396_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379:150\u201361.","journal-title":"N Engl J Med"},{"key":"1396_CR7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","volume":"28","author":"T Todo","year":"2022","unstructured":"Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630\u20139.","journal-title":"Nat Med"},{"key":"1396_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-022-00921-3","volume":"7","author":"D Song","year":"2022","unstructured":"Song D, Jia X, Liu X, Hu L, Lin K, Xiao T, et al. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct Target Ther. 2022;7:100.","journal-title":"Signal Transduct Target Ther"},{"key":"1396_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/hum.2016.038","volume":"27","author":"H Zhang","year":"2016","unstructured":"Zhang H, Lin Y, Li K, Liang J, Xiao X, Cai J, et al. Naturally, existing oncolytic virus M1 is nonpathogenic for the nonhuman primates after multiple rounds of repeated intravenous injections. Hum Gene Ther. 2016;27:700\u201311.","journal-title":"Hum Gene Ther"},{"key":"1396_CR10","doi-asserted-by":"crossref","unstructured":"Xie C, Zheng X, He S, Xu W, Zhu W, Yan G, et al. Clinical evaluation of M1-c6v1 oncolytic virus combined with camrelizumab and apatinib in advanced hepatocellular carcinoma. Clin Cancer Res. 2025;31:4288\u201398.","DOI":"10.1158\/1078-0432.CCR-25-1620"},{"key":"1396_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03285-0","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cai J, Liu W, Lin Y, Guo L, Liu X, et al. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell Death Dis. 2020;11:1062.","journal-title":"Cell Death Dis"},{"key":"1396_CR12","unstructured":"U.S. Food & Drug Administration. (2022, 09, 12). Search orphan drug designations and approvals: recombinant oncolytic virus based on the backbone of Alphavirus M1. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=897922."},{"key":"1396_CR13","doi-asserted-by":"publisher","first-page":"24694","DOI":"10.18632\/oncotarget.15788","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, Cheng H, Xiong XW, Yuan L, Peng ZH, Wen ZW, et al. Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. Oncotarget. 2017;8:24694\u2013705.","journal-title":"Oncotarget"},{"key":"1396_CR14","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1038\/s41388-021-01869-4","volume":"40","author":"J Zhang","year":"2021","unstructured":"Zhang J, Liu Y, Tan J, Zhang Y, Wong CW, Lin Z, et al. Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene. 2021;40:4783\u201395.","journal-title":"Oncogene"},{"key":"1396_CR15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/ijc.33703","volume":"149","author":"W Liu","year":"2021","unstructured":"Liu W, Liu Y, Hu C, Xu C, Chen J, Chen Y, et al. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 by targeting regulatory T cells. Int J Cancer. 2021;149:1369\u201384.","journal-title":"Int J Cancer"},{"key":"1396_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","volume":"9","author":"HS Phillips","year":"2006","unstructured":"Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157\u201373.","journal-title":"Cancer Cell"},{"key":"1396_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23:445\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"1396_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","volume":"24","author":"P Chongsathidkiet","year":"2018","unstructured":"Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24:1459\u201368.","journal-title":"Nat Med"},{"key":"1396_CR19","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1073\/pnas.1701002114","volume":"114","author":"J Cai","year":"2017","unstructured":"Cai J, Lin Y, Zhang H, Liang J, Tan Y, Cavenee WK, et al. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc Natl Acad Sci USA. 2017;114:6812\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1396_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ymthe.2020.02.017","volume":"28","author":"MS Ferguson","year":"2020","unstructured":"Ferguson MS, Chard Dunmall LS, Gangeswaran R, Marelli G, Tysome JR, Burns E, et al. Transient inhibition of PI3Kdelta enhances the therapeutic effect of intravenous delivery of oncolytic vaccinia virus. Mol Ther. 2020;28:1263\u201375.","journal-title":"Mol Ther"},{"key":"1396_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1089\/hum.2020.114","volume":"31","author":"J Cai","year":"2020","unstructured":"Cai J, Zhu W, Lin Y, Zhang S, Chen X, Gong S, et al. Systematic characterization of the biodistribution of the oncolytic virus M1. Hum Gene Ther. 2020;31:1203\u201313.","journal-title":"Hum Gene Ther"},{"key":"1396_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432\u201347.","journal-title":"Cell Mol Immunol"},{"key":"1396_CR23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nri1245","volume":"3","author":"JB Huppa","year":"2003","unstructured":"Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol. 2003;3:973\u201383.","journal-title":"Nat Rev Immunol"},{"key":"1396_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44688-3","volume":"15","author":"C Lacouture","year":"2024","unstructured":"Lacouture C, Chaves B, Guipouy D, Houmadi R, Duplan-Eche V, Allart S, et al. LFA-1 nanoclusters integrate TCR stimulation strength to tune T-cell cytotoxic activity. Nat Commun. 2024;15:407.","journal-title":"Nat Commun"},{"key":"1396_CR25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/2159-8290.CD-22-0455","volume":"13","author":"Z Ye","year":"2023","unstructured":"Ye Z, Ai X, Yang K, Yang Z, Fei F, Liao X, et al. Targeting microglial metabolic rewiring synergizes with immune-checkpoint blockade therapy for glioblastoma. Cancer Discov. 2023;13:974\u20131001.","journal-title":"Cancer Discov"},{"key":"1396_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202208782","volume":"35","author":"S Lugani","year":"2023","unstructured":"Lugani S, Halabi EA, Oh J, Kohler RH, Peterson HM, Breakefield XO, et al. Dual immunostimulatory pathway agonism through a synthetic nanocarrier triggers robust anti-tumor immunity in murine glioblastoma. Adv Mater. 2023;35:e2208782.","journal-title":"Adv Mater"},{"key":"1396_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22885-8","volume":"12","author":"Z Amoozgar","year":"2021","unstructured":"Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582.","journal-title":"Nat Commun"},{"key":"1396_CR28","doi-asserted-by":"crossref","unstructured":"Li J, Ross JL, Hambardzumyan D, Brat DJ. Immunopathology of glioblastoma. Annu Rev Pathol. 2026;21:135\u201362.","DOI":"10.1146\/annurev-pathmechdis-042524-025950"},{"key":"1396_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101975","volume":"79","author":"R Piranlioglu","year":"2025","unstructured":"Piranlioglu R, Chiocca EA. Oncolytic virus-mediated immunomodulation in glioblastoma: insights from clinical trials and challenges. Semin Immunol. 2025;79:101975.","journal-title":"Semin Immunol"},{"key":"1396_CR30","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21:1354\u201375.","journal-title":"Cell Mol Immunol"},{"key":"1396_CR31","first-page":"2583","volume":"62","author":"T Yang","year":"2002","unstructured":"Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 2002;62:2583\u201391.","journal-title":"Cancer Res"},{"key":"1396_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01724-w","volume":"39","author":"H Hosseinalizadeh","year":"2022","unstructured":"Hosseinalizadeh H, Mahmoodpour M, Samadani AA, Roudkenar MH. The immunosuppressive role of indoleamine 2,3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies. Med Oncol. 2022;39:130.","journal-title":"Med Oncol"},{"key":"1396_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, et al. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity. 2025;58:232\u201346.e6.","journal-title":"Immunity"},{"key":"1396_CR34","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1172\/JCI97973","volume":"128","author":"C Wu","year":"2018","unstructured":"Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018;128:3425\u201338.","journal-title":"J Clin Invest"},{"key":"1396_CR35","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s42255-025-01279-w","volume":"7","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xu M, Sun J, Li X, Shi H, Wang X, et al. Author Correction: Glycolytic neutrophils accrued in the spleen compromise antitumor T-cell immunity in breast cancer. Nat Metab. 2025;7:854.","journal-title":"Nat Metab"},{"key":"1396_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi3487","volume":"9","author":"DM Morgan","year":"2024","unstructured":"Morgan DM, Horton BL, Bhandarkar V, Van R, Dinter T, Zagorulya M, et al. Expansion of tumor-reactive CD8(+) T-cell clonotypes occurs in the spleen in response to immune checkpoint blockade. Sci Immunol. 2024;9:eadi3487.","journal-title":"Sci Immunol"},{"key":"1396_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2024.11.008","volume":"36","author":"TG Chang","year":"2025","unstructured":"Chang TG, Spathis A, Schaffer AA, Gavrielatou N, Kuo F, Jia D, et al. Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer. Ann Oncol. 2025;36:309\u201320.","journal-title":"Ann Oncol"},{"key":"1396_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-025-03318-6","volume":"44","author":"Z Li","year":"2025","unstructured":"Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z. Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade. J Exp Clin Cancer Res. 2025;44:84.","journal-title":"J Exp Clin Cancer Res"},{"key":"1396_CR39","doi-asserted-by":"crossref","unstructured":"Meylan M, Petitprez F, Becht E, Bougo\u00fcin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55:527\u201341.","DOI":"10.1016\/j.immuni.2022.02.001"},{"key":"1396_CR40","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.1021\/acsnano.4c15113","volume":"19","author":"C Li","year":"2025","unstructured":"Li C, Ke F, Mao S, Montemayor Z, Traore MDM, Balsa AD, et al. SARS-CoV-2 B epitope-guided neoantigen nanovaccines enhance tumor-specific CD4\/CD8 T-cell immunity through B-cell antigen presentation. ACS Nano. 2025;19:7038\u201354.","journal-title":"ACS Nano"},{"key":"1396_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.biocel.2014.10.005","volume":"57","author":"S Han","year":"2014","unstructured":"Han S, Feng S, Ren M, Ma E, Wang X, Xu L, et al. Glioma cell-derived placental growth factor induces regulatory B cells. Int J Biochem Cell Biol. 2014;57:63\u20138.","journal-title":"Int J Biochem Cell Biol"},{"key":"1396_CR42","doi-asserted-by":"crossref","unstructured":"Hou D, Wang S, Castro BA, Katz JL, Dapash M, Arrieta VA, et al. Dual alphaVbeta8 integrin and PD-1 blockade overcomes TGFbeta-mediated B-cell suppression to enhance anti-tumor immunity. Neuro Oncol. 2025;27:2355\u201369.","DOI":"10.1093\/neuonc\/noaf106"},{"key":"1396_CR43","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/2326-6066.CIR-19-0240","volume":"7","author":"C Lee-Chang","year":"2019","unstructured":"Lee-Chang C, Rashidi A, Miska J, Zhang P, Pituch KC, Hou D, et al. Myeloid-derived suppressive cells promote B-cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunol Res. 2019;7:1928\u201343.","journal-title":"Cancer Immunol Res"},{"key":"1396_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ccell.2024.12.006","volume":"43","author":"J Gao","year":"2025","unstructured":"Gao J, Gu D, Yang K, Zhang J, Lin Q, Yuan W, et al. Infiltrating plasma cells maintain glioblastoma stem cells through IgG-tumor binding. Cancer Cell. 2025;43:122\u201343.e8.","journal-title":"Cancer Cell"},{"key":"1396_CR45","doi-asserted-by":"crossref","unstructured":"Lee-Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga RA, et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNgamma elicits potent immunity against glioblastoma. J Exp Med. 2021;218:e20200913.","DOI":"10.1084\/jem.20200913"},{"key":"1396_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04709-z","volume":"21","author":"Z Shen","year":"2023","unstructured":"Shen Z, Liu X, Fan G, Na J, Liu Q, Lin F, et al. Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages. J Transl Med. 2023;21:842.","journal-title":"J Transl Med"},{"key":"1396_CR47","doi-asserted-by":"crossref","unstructured":"Hwang JK, Hong J, Yun CO. Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials. Int J Mol Sci. 2020;21:8627.","DOI":"10.3390\/ijms21228627"},{"key":"1396_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103362","volume":"86","author":"P Lau","year":"2025","unstructured":"Lau P, Liang L, Chen X, Zhang J, Liu H. Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis. EClinicalMedicine. 2025;86:103362.","journal-title":"EClinicalMedicine"},{"key":"1396_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31262-y","volume":"13","author":"T Todo","year":"2022","unstructured":"Todo T, Ino Y, Ohtsu H, Shibahara J, Tanaka M. A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma. Nat Commun. 2022;13:4119.","journal-title":"Nat Commun"},{"key":"1396_CR50","first-page":"925s","volume":"7","author":"W von Bernstorff","year":"2001","unstructured":"von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, J\u00f6hnk C, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7:925s\u201332s.","journal-title":"Clin Cancer Res"}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01396-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01396-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01396-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:03:06Z","timestamp":1774940586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-026-01396-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1038\/s41423-026-01396-w","relation":{},"ISSN":["2042-0226"],"issn-type":[{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WZ and GY hold equity in Guangzhou Virotech Pharmaceutical Technology Co., Ltd. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}